Nirsevimab alip Beyfortus is generally recommended for all infants

By rray, 31 October, 2023
Exclude Patient Type Detail Header
No
Footnote
<sup>1</sup> <b>CDC CPR 2023.</b> Center for Preparedness and Response. <i>Limited Availability of Nirsevimab in the United States—Interim CDC Recommendations to Protect Infants from Respiratory Syncytial Virus (RSV) during the 2023–2024 Respiratory Virus Season.</i> October 23, 2023. CDCHAN-00499. <a href=https://emergency.cdc.gov/han/2023/han00499.asp><u>Accessed October 25, 2023</u></a>
<br><br>
<sup>2</sup> <b>AAP 2014.</b> American Academy of Pediatrics Committee on Infectious Diseases and Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. <i>Pediatrics.</i> 2014 Aug;134(2):415-20. <a href=https://publications.aap.org/pediatrics/article/134/2/415/33013/Updated-Guidance-for-Palivizumab-Prophylaxis-Among><u>Free, full-text article</u></a>
<br><br>
<sup>3</sup> <b>ACIP and AAP 2023.</b> ACIP and AAP Recommendations for the Use of the Monoclonal Antibody Nirsevimab for the Prevention of RSV Disease. American Academy of Pediatrics website. August 15, 2023. <a href=https://publications.aap.org/redbook/resources/25379/ACIP-and-AAP-Recommendations-for-Nirsevimab><u>Accessed October 25, 2023</u></a>
Detail Type
Text
Detail Text
Infants weighing
Infants weighing 5 kg 11 lb Avoid using two 50 mg nirsevimab doses Prioritize using 100 mg doses in those at highest risk of severe RSV dz 1 nbsp Infants
Palivizumab eligible infants
Palivizumab eligible children 8 19 mo Suspend use of nirsevimab for the 2023 2024 RSV season and give palivizumab Synagis 1 2 nbsp Palivizumab ppx is recommended for infants in the 1st year of life born before 29 wk gestation preterm infants in the 1st ye
American Indian and Alaska Native children 8 19 mo Continue offering nirsevimab to those not eligible for palivizumab who live in remote regions or in communities w high rates of severe RSV among older infants and toddlers 1
Pregnant pts Encourage them to receive Abrysvo respiratory syncytial virus vaccine RSVpreF at 32 36 wk gestation during RSV season Sept Jan in most of the U S Don t use Arexvy RSVPreF3 in pregnant pts Administration of both Abrysvo to pregnant pts and nir
Patient Type Detail Header (Long)
<a href=https://online.epocrates.com/e/deeplink/drugs/10a11222/Beyfortus%20(nirsevimab-alip)><u><b>Nirsevimab-alip (Beyfortus)</b></u></a> is generally recommended for all infants <8 mo born during or entering their 1st RSV season and for infants and children 8-19 mo at increased risk for severe RSV dz and entering their 2nd RSV season. However, due to <b>limited supply</b> during the 2023-2024 RSV season, CDC has developed the following interim recommendations:<sup>1</sup>